|
US2009023814A1
|
|
Compositions and methods having mt1 receptor activity
|
|
US2008207766A1
|
|
Methods and compositions for treating at least one upper gastrointestinal symptom
|
|
WO2008090471A2
|
|
Use of compositions comprising at least one alfa3 beta4 nachr antagonist such as mecamylamine in the treatment of gastrointestinal disorders
|
|
MX2009000923A
|
|
Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity.
|
|
EP1871393A2
|
|
Acarbose methods and formulations for treating chronic constipation
|
|
US2006222709A1
|
|
Metformin methods and formulations for treating chronic constipation
|
|
NZ542260A
|
|
Treatment of intestinal conditions with mecamylamine
|
|
NZ539059A
|
|
Use of (R)-verapamil for the treatment of abnormal increases in gastrointestinal motility
|
